Press release
KRAS Inhibitors Market Report on the Untapped Growth Opportunities in the Industry
According to the latest research by InsightAce Analytic, the Global KRAS Inhibitors Market Size is valued at USD 476.0 Mn in 2024 and is predicted to reach USD 2,916.8 Mn by the year 2034 at a 20.0% CAGR during the forecast period for 2025-2034.
Request For Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/2251
The KRAS gene encodes the K-Ras protein, a pivotal component of the RAS/MAPK signaling pathway. This pathway transmits signals from outside the cell to the nucleus, influencing cell proliferation, differentiation, and survival. Mutations in KRAS can lead to uncontrolled cell growth, contributing to the development of various cancers, including lung, colorectal, and pancreatic cancers.
Historically considered "undruggable," KRAS has become a focal point in oncology research. Recent breakthroughs have led to the development of small-molecule inhibitors targeting specific KRAS mutations, such as G12C and G12D. Notably, drugs like sotorasib and adagrasib have received FDA approval for treating non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations. Additionally, emerging therapies like zoldonrasib have shown promise in early-phase clinical trials, demonstrating tumor shrinkage in patients with KRAS G12D mutations .
List of Prominent Players in the KRAS Inhibitors Market:
• Amgen
• Boehringer Ingelheim
• BridgeBio Pharma
• Erasca
• Innovent Biologics, Inc.
• Incyte
• Mirati Therapeutics
• Novartis
• Jemincare
• Cardiff Oncology, Inc.
• Roche
• Genentech
• Verastem Oncology
• Revolution Medicines
• Immuneering Corporation
• Jacobio Pharmaceuticals
• Deciphera Pharmaceuticals
• Elicio Therapeutics
• InventisBio
• Gritstone Bio
• D3 Bio
• Others
Market Dynamics:
Drivers-
The increasing demand for KRAS inhibitors is being propelled by the rising adoption of targeted therapies in oncology. These therapies have gained significant traction due to their precision and effectiveness in treating various forms of cancer. This report provides an in-depth analysis of the current therapeutic pipeline and explores the future trajectory of KRAS inhibitor research. It also presents comprehensive commercial insights into KRAS inhibitors currently available in the market and the overall pipeline landscape for this mechanism of action.
Curious about this latest version of the report? Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/2251
Challenges:
The KRAS inhibitors market faces several notable challenges. Regulatory complexities, a shortage of skilled professionals, and the absence of standardized protocols-particularly in emerging economies-have created barriers to market growth. These issues were further intensified by the lockdowns and isolation measures brought about by the COVID-19 pandemic, which disrupted ongoing clinical trials.
Regional Trends:
North America is expected to lead the KRAS inhibitors market in terms of revenue and is projected to experience strong compound annual growth over the forecast period. This trend is primarily driven by increased investment in R&D and a rising incidence of cancers associated with KRAS mutations.
Europe also holds a considerable share of the market, underpinned by technological advancements and higher healthcare spending. Key factors supporting market expansion across these regions include the growing demand for targeted oncology therapies, improvements in healthcare infrastructure, a notable prevalence of KRAS mutations across cancer types, and the accelerating pace of drug discovery and clinical development.
Recent Developments:
• In October 2022, At the AACR annual meeting, Novartis presented encouraging clinical results for JDQ443, an experimental selective, covalent, and orally accessible KRASG12C inhibitor. A poster on Wednesday, April 13, and Cancer Discovery1 provide detailed information about JDQ443's discovery. JDQ443, discovered at Novartis, showed anti-tumor activity, high systemic exposure at its necessory dose, and a favorable safety profile in patients with KRAS G12C-mutated solid tumors in Phase Ib of the KontRASt-01 study (NCT04699188)2. In an oral session, the late-breaking abstract data will be presented.
• In September 2023, Amgen reported promising results from a specific part of the CodeBreaK 101 clinical trial, which is a Phase 1b research investigating the effectiveness of LUMAKRAS® (sotorasib) in combination with carboplatin and pemetrexed for treating adult patients with advanced non-small cell lung cancer (NSCLC) that contains a specific genetic mutation called KRAS G12C. The aforementioned findings were presented orally at the 2023 World Conference on Lung Cancer (WCLC), organized by the IASLC.
Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/2251
Segmentation of KRAS Inhibitors Market-
By Cancer Type-
• Lung Cancer
• Pancreatic Cancer
• Colorectal Cancer
• Others
By End-Use-
• Clinic Laboratories
• Cancer Diagnostic Centers
• Hospitals
• Cancer Research Institutes
• Academic Institutions
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa
Get More Information: @
https://www.insightaceanalytic.com/report/kras-inhibitors-market/2251
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.JPG
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release KRAS Inhibitors Market Report on the Untapped Growth Opportunities in the Industry here
News-ID: 4067877 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
Sack Fillers Market Deep Research Report with Forecast to 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Sack Fillers Market Size, Share & Trends Analysis Report By Sack Type (Open Mouth Sack, and Valve Sack), Technology Type (Semi-Automatic Sack Fillers, Automatic Sack Fillers), Machine Type (Horizontal Sack Fillers, Vertical Sack Fillers), Capacity (Below 500 Bags/hr, 500-1000 Bags/hr, 1000-1500 Bags/hr, and More Than 1500 Bags/hr), End Use (Food Industry, Pharmaceuticals, Household & Personal…
Wire Cerclage Sternal Closure Systems Market Growth and Restrain Factors Analysi …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Wire Cerclage Sternal Closure Systems Market Size, Share & Trends Analysis Report By Product Type (Bone Cement, Closure Devices), Material (Polyether Ether (PEEK), Titanium, Stainless Steel), Procedure (Hemisternotomy, Median Sternotomy, Bilateral Thoracosternotomy), Region, Market Outlook And Industry Analysis 2031"
The Global Wire Cerclage Sternal Closure Systems Market is estimated to reach over USD 5.67 billion…
Variable Life Insurance Market Size, Share and Trends Analysis Report 2025-2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Variable Life Insurance Market Size, Share & Trends Analysis Report By Type (Fixed Premium, Variable Universal Life Insurance), By Components (Death Benefits, Add-On Benefits), By End-User (Agency, Brokers, Bancassurance, Digital And Direct Channel), Region, Market Outlook And Industry Analysis 2034"
The Global Variable Life Insurance Market is estimated to reach over USD 241.6 Bnby 2034, exhibiting…
Smart Vineyard Management Market Survey Detailed Analysis and Forecast 2025-2034
on the "Global Smart Vineyard Management Market Size, Share & Trends Analysis Report By Product (Hardware, Software, Services), By Hardware (Robots & Drones, Sensors), By Software (On-Cloud Software v/s On-Premises Software), By Services (Professional v/s Managed), By Technology (Guidance, Sensing, Variable Rate Technology), By Application (Yield Monitoring, Crop Scouting, Harvesting, Irrigation Management), Region, Market Outlook And Industry Analysis 2034"
The global smart vineyard management market is estimated to reach over USD…
More Releases for KRAS
KRAS Inhibitor Market Set to Grow by 35%: Revolutionary Pan-KRAS Pipeline Develo …
DelveInsight's comprehensive analysis reveals the KRAS inhibitors market is experiencing unprecedented growth, with breakthrough therapies targeting multiple mutation variants and significant FDA approvals transforming treatment landscapes for oncology patients. Major pharmaceutical companies including Roche, Revolution Medicines, Eli Lilly, Verastem Oncology, Bristol Myers Squibb, and Amgen are leading this therapeutic revolution.
Key Insights on KRAS Inhibitor Market
*
Market size projection: As per DelveInsight's analysis, the total market size of KRAS inhibitors in the…
Targeting KRAS Mutations in Cancer Therapy
Targeting KRAS mutations has been an ongoing focus in cancer therapy, providing novel treatment options for patients with these mutation-driven malignancies. KRAS is an important gene in cell signaling pathways that control cell growth and division. Mutations in this gene cause excessive cell proliferation, which contributes to the development and progression of many malignancies, including lung, colorectal, and pancreatic cancer.
Download Report:
https://www.kuickresearch.com/report-kras-inhibitors-market-lumakras-sales-kras-drugs-market-kras-market-size
For many years, KRAS was thought to be an intractable…
New Hope for Cancer Patients with KRAS Inhibitors
The development of KRAS inhibitors has given cancer patients new hope, particularly those with KRAS mutations. KRAS is one of the most frequently mutated genes in human malignancies, with a critical involvement in cell signaling pathways that drive cell growth and division. Mutations in this gene cause excessive cell proliferation, which contributes to the development of several malignancies, including lung, colorectal, and pancreatic cancer.
Download Report:
https://www.kuickresearch.com/report-kras-inhibitors-market-lumakras-sales-kras-drugs-market-kras-market-size
For many years, addressing KRAS mutations…
Advances in KRAS Inhibitor Development
The development of KRAS inhibitors has been a significant advancement in the field of oncology, offering new hope for patients with cancers driven by KRAS mutations. KRAS, a key gene involved in cell signaling, is frequently mutated in various cancers, including lung, colorectal, and pancreatic cancers. These mutations lead to uncontrolled cell growth and division, making KRAS a critical target for cancer therapy.
Download Report:
https://www.kuickresearch.com/report-kras-inhibitors-market-lumakras-sales-kras-drugs-market-kras-market-size
Historically, KRAS was considered an undruggable target…
How KRAS Inhibitors Are Transforming Cancer Therapy
The advent of KRAS inhibitors represents a paradigm shift in cancer therapy, particularly for cancers driven by KRAS mutations. KRAS is a critical gene involved in cell signaling pathways that regulate cell growth and division. Mutations in this gene lead to uncontrolled cell proliferation, contributing to the development and progression of various cancers, including lung, colorectal, and pancreatic cancers.
Download Report:
https://www.kuickresearch.com/report-kras-inhibitors-market-lumakras-sales-kras-drugs-market-kras-market-size
For many years, KRAS was considered an undruggable target due to…
Breakthroughs in KRAS Inhibitor Research
KRAS mutations have posed a significant challenge in oncology for decades, but recent breakthroughs in KRAS inhibitor research have sparked hope for new cancer therapies. KRAS is a key regulator of cell growth and survival, and its mutations are prevalent in various cancers, particularly lung, colorectal, and pancreatic cancers. Despite being one of the most sought-after targets, KRAS has been notoriously difficult to inhibit, earning the reputation of being "undruggable."
Download…
